Selection of Excipients in Generic Formulations

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-04-15-2014
Volume 2014 eBook
Issue 1

The selection of excipients is important in generic formulations due to the impact it has on the risk and performance of generic drugs.

The selection of excipients is important in generic formulations due to the impact it has on the risk and performance of generic drugs.

Download

Pharmaceutical Technology’s 2014 Solid Dosage and Excipients eBook

.

 

 

 

 

 

 

 

 

Articles in this issue
PTe0414_Colorcon.jpg
Safety by Design—Mitigating the Risk of Medication Errors Through Product Design
PTe0414_controlled.jpg
Controlled-Release Technologies Create Opportunities for Solid-Dosage Drug Formulators
pte0414_hausnervideo.jpg
Continuous Manufacturing for Solid-Dosage Drug Production
PTe0414_Hovione.jpg
A Practical Guide to Hot-Melt Extrusion Scale-Up for Pharmaceutical Applications
PTe0414_ModWave.jpg
Using Modular Systems in Solid-Dosage Manufacturing
pte0414_Martinvideo.jpg
Advances in Hot-Melt Extrusion Manufacturing
PTe0414_Bohle.jpg
Obtaining User-Defined Particle Size Distribution Using Dry Granulation
PTe0414_evonik.jpg
A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D
PTe0414Generic.jpg
Selection of Excipients in Generic Formulations
Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Incyte, Genesis Therapeutics to Use AI Platform to Discover Small Molecule Compounds

Patrick Lavery
February 21st 2025
Article

The collaboration will utilize Genesis’ proprietary AI platform, initially focusing on targets selected by Incyte.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Google Launches AI Co-Scientist System

Susan Haigney
February 20th 2025
Article

The AI co-scientist is a multi-agent AI system that can work as a virtual scientific collaborator.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

MMS Acquires Exploristics and Its Flagship Modeling and Simulation Platform

Patrick Lavery
February 14th 2025
Article

In seeking a data-driven approach to efficient drug development, MMS aims to enhance its capabilities in advanced clinical trial design, innovative statistics, and data science with the acquisition.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Axplora Announces €50 Million Investment in GLP-1 Manufacturing in France

Patrick Lavery
February 13th 2025
Article

This site was previously the beneficiary of a €7.3 million (US$7.6 million) investment, made in 2022, earmarked for the production of HPAPIs to treat cancer.